1. Scrip
  2. >>R&D
  3. >>Clinical Trials

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

Targets Key Regulator Of Neurotransmitters

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Neurocrine Biosciences
Neurocrine Biosciences reports further details of Phase II findings for its novel schizophrenia candidate. • Source: Alamy

Neurocrine Biosciences’ NBI-1117568 has shown significant improvement in symptoms and overall severity in adults with schizophrenia in new data presented from a Phase II dose-finding study, and the company is now moving the asset into a roughly 280-patient Phase III registrational program.

NBI-1117568 is the first investigational oral selective muscarinic M4 orthosteric agonist in clinical development as a potential treatment for schizophrenia;...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.